Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Conference Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO Conference Call Participants Ryan Deschner - Raymond James Mike Ulz - Morgan Stanley Asim Rana - Truist Securities Jay Olson - Oppenheimer Annabel Samimy - Stifel Mayank Mamtani - B. Riley Securities Biren Amin - Piper Sandler Hardik Parikh - JPMorgan Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Prediction: This Pharma Stock Will Be the Best Performer in 2025
Market uncertainty can make nervous investors leery of investing in industries that are more speculative in nature, such as pharmaceuticals and biotechnology.
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.
Why this Weight-Loss Drug Stock Could Gain 200%
There are several potential challengers to Novo Nordisk and Eli Lilly's obesity drugs, and Jefferies analysts see one as particularly promising.
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared.
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking's obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
